Search Results - "Guest, Ryan D."
-
1
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity
Published in Cancer Immunology, Immunotherapy (01-11-2017)“…The primary aim of this clinical trial was to determine the feasibility of delivering first-generation CAR T cell therapy to patients with advanced, CEACAM5 +…”
Get full text
Journal Article -
2
Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma
Published in American journal of cancer research (01-01-2022)“…Nonselected autologous tumor-infiltrating lymphocytes (TILs) may provide advantages over other treatments for solid tumors, including checkpoint…”
Get full text
Journal Article -
3
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: Evaluation of four different scFvs and antigens
Published in Journal of immunotherapy (1997) (01-05-2005)“…Human peripheral blood lymphocytes can be transduced to express antigen-dependent CD3zeta chimeric immune receptors (CIRs), which function independently of the…”
Get full text
Journal Article -
4
Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial
Published in Cancer Immunology, Immunotherapy (01-02-2014)“…Adoptive cell therapy employing gene-modified T-cells expressing chimeric antigen receptors (CARs) has shown promising preclinical activity in a range of model…”
Get full text
Journal Article -
5
177 Treatment outcomes with unselected autologous tumor infiltrating lymphocytes in patients with checkpoint inhibition–refractory advanced cutaneous melanoma
Published in Journal for immunotherapy of cancer (01-11-2021)“…BackgroundTumor infiltrating lymphocyte (TIL) products made from tumor digests showed a high overall response rate (ORR; 67%) and complete response (CR) rate…”
Get full text
Journal Article -
6
059 Role of cryopreservation in the clinical delivery of T cell based adoptive cell therapies (ACT)
Published in Cryobiology (01-12-2013)“…The development of Adoptive Cell Therapy (ACT) based immunotherapies using either naturally-occurring or genetically engineered T cells to target tumours have…”
Get full text
Journal Article -
7
-
8
Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases
Published in Diseases of the colon & rectum (01-06-2003)“…The overall aim of this study was to develop a novel treatment for colorectal cancer based on the use of gene therapy. Genetic modification of T lymphocytes…”
Get more information
Journal Article -
9
Cryopreservation of T cells for adoptive T cell therapy
Published in Cryobiology (01-12-2015)Get full text
Journal Article -
10
P53 integrity in the genetically engineered mammalian cell lines AHH-1 and MCL-5
Published in Mutation research (25-01-1999)“…Recently, a C to T transition mutation in exon 8 of the p53 gene has been identified in a subculture of the genetically engineered human lymphoblastoid cell…”
Get more information
Journal Article -
11
Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors
Published in Journal of immunotherapy (1997) (01-03-2002)“…Antigen-specific T lymphocytes are attractive as potential anticancer agents. The generation of large numbers of antigen-specific T cells is possible through…”
Get full text
Journal Article